Report Code: A08427 | Pages: NA | Jul 2023 | 1907 Views | ||
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Intranasal Drug And Vaccine Delivery Market
Request Now !Various bacteria and microorganisms can enter the body to for a new infection via various mucosal sites. There is a huge amount of vaccines licensed at the moment that are parenterally administered. They can build strong immunity but cannot generate mucosal immunity. Nasal vaccinations are used on a large scale for the foundation of immunity for infections, which specifically enter through the mucus. Administration through mucosal sites, especially through nasal route, adds up to the promising and alternative measures for the delivery of vaccines and drugs. These routes have various benefits, which help in several pathologies. Various key players work on the innovation of novel drugs and other devices for the vaccine delivery through the nasal route. Furthermore, various evidences help in the adoption of drugs and vaccines through the nasal route for safety. In recent years, there have been various doubts for the nasal delivery of drugs and vaccines, but this sector of healthcare has been growing at an accelerating rate.
COVID-19 scenario analysis:
Rise in frequencies of neurological and respiratory disorders and increase in regards to intranasal product launches are the major factors that propel the growth of the intranasal drug and vaccine delivery market. There has been significant rise in demand for nasal products, which are non-invasive and skillfully tolerated by the patients. There are other upgrades underway in technology with regards to the nasal drug delivery systems. It has been scientifically proved that nasal drug deliveries are useful for central nervous system disease treatment as the nasal route directly connects the nervous system even when there is a barrier of blood-brain connections.
An increase has been observed in prescriptions for non-invasive drugs, which work on the nasal delivery routes to treat various chronic disorders such as allergies, rhinitis, CNS diseases, and migraine. Therefore, this affects the growth of the intranasal drug and vaccine delivery market positively. On the other hand, there have been various complexities and side effect related to nasal products, which are the major challenge faced by the intranasal drug and vaccine delivery market.
On February 5th, 2020, Nemera developed an electronic nasal spray, Safe’n’Spray. This device received an award at Pharmapack for best innovation. On July 25th, 2019, the U.S. Food and Drug Administration (FDA) approved the Unidose Powder system, which was launched by AptarGroup, Inc. On July 3rd, 2019, Insys Therapeutics, Inc. got an approval from the U.S. FDA for its new drug application unit-dose naloxone nasal spray. This spray is used for the treatment of opioid overdose. On March 19th, 2019, Aptar Pharma got approval from the U.S. FDA. This approval was received for its new product, Bidose nasal spray device. This device was used for the treatment of depression.
Retail pharmacies, online pharmacies, and hospital pharmacies are the major consumers of the intranasal drug and vaccine delivery market. Amongst them, retail pharmacies are the biggest end-users of the market. This is attributed to the significant rise in the positive outcomes of medicines, raise in awareness, and self-administration. Moreover, various developers of these devices collaborate for the betterment of the pharmacy chains.
Along with this, various online pharmacies are also rising in the past few years, owing to the discounted offers granted by the owners of online portals. Additionally, lower costs attract the payers as well as the patients.
Key benefits of the report:
Questions answered in the intranasal drug and vaccine delivery market research report:
Intranasal Drug and Vaccine Delivery Market: Global Opportunity Analysis and Industry Forecast 2020–2027 Report Highlights
Aspects | Details |
---|---|
By Product |
|
By Dosage |
|
By Application |
|
By End User |
|
By Region |
|
Key Market Players | UCB, Inc., GlaxoSmithKline Plc, Teleflex Corporation, Bespak, 3M, OptiNose, Inc., Intersect ENT, Teva Pharmaceuticals, Aptar Pharma |
Loading Table Of Content...
Start reading.
This Report and over 53,705+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers